Navigation Links
BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
Date:10/25/2007

WOBURN, Mass., Oct. 25 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that it has appointed Jan van Heek, age 58, as Chairman of the Board of Directors.

Mr. van Heek is employed as a Senior Advisor to the CEO and the senior management team of Genzyme Corporation; he joined Genzyme in 1991 and has been responsible for building the Company's worldwide therapeutics, surgical and genetic testing businesses. He established Genzyme's European offices in the early 1990's before moving to the U.S. to head the Company's therapeutics division. Mr. van Heek has played a key role in building Genzyme's broad portfolio of businesses and manufacturing infrastructure worldwide. Prior to Genzyme, Mr. van Heek held various management positions at Baxter Healthcare Corporation in Europe and the U.S. At Baxter, his last position was as vice president/general manager of the global Fenwal Division of Baxter Healthcare Corporation based in Deerfield, Illinois. Mr. van Heek is a board member of Viacell Corporation, Zelos Corporation and PanGenetics BV. He received an M.B.A. from St. Gallen University, Switzerland and an executive degree from Stanford Business School, California.

Philip Astley-Sparke, President & CEO of BioVex Inc, said:

"Jan's appointment brings to the Board nearly two decades of experience in managing the commercial and manufacturing operations of one the world's preeminent biotechnology companies."

Jan van Heek, Chairman of BioVex Inc, said:

"I am excited to be joining BioVex at a transformational time in its development as it scales up its manufacturing operations to produce launch grade material. I look forward to working with the management team, the Board and the Company's investors in implementing the Company's substantial growth plans over the next year and beyond."

About BioVex

BioVex is a privately held biotechnology Company based in Woburn. MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

BioVex's lead cancer program, OncoVEX GM-CSF, is an oncolytic virus that selectively destroys tumor cells accompanied by the induction of a systemic immune response. OncoVEX GM-CSF is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer. Preliminary data from these studies has been very encouraging demonstrating OncoVEX GM-CSF has the potential to treat both local and metastatic disease. The Company is currently preparing for an initial registration study in melanoma where multiple responses have been demonstrated in an ongoing Phase II trial testing OncoVEX GM-CSF as stand alone therapy in patients with un-resectable stage IIIc and stage IV metastatic disease.

The Company's second program is a vaccine for genital herpes, ImmunoVEX HSV2, which provides complete protection in animal models of the disease. A Phase I study with ImmunoVEX HSV2 is scheduled to initiate later this year.

For more information visit the company's website at http://www.biovex.com.


'/>"/>
SOURCE BioVex Inc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):